Sesen Bio (SESN) Stock Price, News & Analysis

Company Overview

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.63 to $12.99
• 52-Week Range: N/A
• Volume: 93,330 shs
• Average Volume: 1.07 million shs
• Market Capitalization: $2.56 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SESN Stock Analysis - Frequently Asked Questions

How were Sesen Bio's earnings last quarter?

Sesen Bio, Inc. (NASDAQ:SESN) issued its quarterly earnings results on Sunday, November, 7th. The company reported $7.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.40) by $8.60.

When did Sesen Bio's stock split?

Sesen Bio shares reverse split before market open on Wednesday, March 8th 2023. The 1-20 reverse split was announced on Wednesday, March 8th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Sesen Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sesen Bio investors own include Predictive Oncology (POAI), Ford Motor (F), Zomedica (ZOM), NIO (NIO), Bank of America (BAC), Wells Fargo & Company (WFC) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 11/07/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SESN
• CUSIP: N/A
• CIK: 1485003
• Web: www.sesenbio.com
• Phone: (617) 444-8550
• Fax: 617-858-0911
• Employees: 35
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-19,880,000.00
• Net Margins: N/A
• Pretax Margin: -59.40%
• Return on Equity: 6.70%
• Return on Assets: 5.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.10
• Quick Ratio: 6.10

Sales & Book Value

• Annual Sales: $40 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 3.39
• Book Value: $0.78 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 203,490,000
• Free Float: 196,980,000
• Market Cap: $2.56 billion
• Optionable: Optionable
• Beta: 0.83